Low-level laser therapy improves vision in patients with age-related macular degeneration.

OBJECTIVE The objective of this study of a case series was to examine the effects of low-level laser therapy (LLLT) in patients with age-related macular degeneration (AMD). BACKGROUND DATA AMD affects a large proportion of the elderly population; current therapeutic options for AMD are limited, however. PATIENTS AND METHODS In total, 203 patients (90 men and 113 women; mean age 63.4 +/- 5.3 y) with beginning ("dry") or advanced ("wet") forms of AMD (n = 348 eyes) were included in the study. One hundred ninety-three patients (mean age 64.6 +/- 4.3 y; n = 328 eyes) with cataracts (n = 182 eyes) or without cataracts (n = 146 eyes) were treated using LLLT four times (twice per week). A semiconductor laser diode (780 nm, 7.5 mW, 292 Hz, continuous emission) was used for transconjunctival irradiation of the macula for 40 sec (0.3 J/cm2) resulting in a total dose of 1.2 J/cm2. Ten patients (n = 20 eyes) with AMD received mock treatment and served as controls. Visual acuity was measured at each visit. Data were analyzed retrospectively using a t-test. RESULTS LLLT significantly improved visual acuity (p < 0.00001 versus baseline) in 162/182 (95%) of eyes with cataracts and 142/146 (97%) of eyes without cataracts. The prevalence of metamorphopsia, scotoma, and dyschromatopsia was reduced. In patients with wet AMD, edema and bleeding improved. The improved vision was maintained for 3-36 mo after treatment. Visual acuity in the control group remained unchanged. No adverse effects were observed in those undergoing therapy. CONCLUSION In patients with AMD, LLLT significantly improved visual acuity without adverse side effects and may thus help to prevent loss of vision.

[1]  F. Holz,et al.  [Age-related macular degeneration. 1. Epidemiology, pathogenesis and differential diagnosis]. , 1996, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[2]  J. Evans Antioxidant vitamin and mineral supplements for age-related macular degeneration. , 2002, The Cochrane database of systematic reviews.

[3]  A. Ramé [Age-related macular degeneration]. , 2006, Revue de l'infirmiere.

[4]  Philip J Rosenfeld,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[5]  J. Evans Antioxidant vitamin and mineral supplements for age-related macular degeneration. , 2000, The Cochrane database of systematic reviews.

[6]  T. Desmettre,et al.  Transpupillary thermotherapy (TTT) with short duration laser exposures induce heat shock protein (HSP) hyperexpression on choroidoretinal layers , 2003, Lasers in surgery and medicine.

[7]  B. Godley,et al.  Oxidative stress-induced mitochondrial DNA damage in human retinal pigment epithelial cells: a possible mechanism for RPE aging and age-related macular degeneration. , 2003, Experimental eye research.

[8]  G. Clover,et al.  The effect of age on the macromolecular permeability of human Bruch's membrane. , 2001, Investigative ophthalmology & visual science.

[9]  G. Hageman,et al.  Age-Related Macular Degeneration (AMD) , 2008 .

[10]  E. Mester,et al.  The biomedical effects of laser application , 1985, Lasers in surgery and medicine.

[11]  Tiina I. Karu,et al.  Photobiological fundamentals of low-power laser therapy , 1987 .

[12]  P. Blomquist,et al.  Etiology of blindness in an urban community hospital setting. , 2001, Ophthalmology.

[13]  Jennifer I. Lim,et al.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. , 2001, Archives of ophthalmology.

[14]  A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss , 2001 .

[15]  R. Ramsay,et al.  New treatments for age-related macular degeneration. , 2009, Minnesota medicine.

[16]  R. Wormald,et al.  Is the incidence of registrable age-related macular degeneration increasing? , 1996, The British journal of ophthalmology.

[17]  Sonia H Yoo,et al.  Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. , 2003, Survey of ophthalmology.

[18]  Aize Kijlstra,et al.  Distribution, markers, and functions of retinal microglia , 2002, Ocular immunology and inflammation.

[19]  F. Holz,et al.  [Pharmacological therapy for age-related macular degeneration. Current developments and perspectives]. , 2003, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.